MedTrace Logo

High-Flow Nasal Cannula on Exercise Tolerance in Heart Failure Patients Undergoing Cardiac Rehabilitation.

NCT07613762 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-05-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a high-flow nasal cannula (HFNC) - a device that delivers warm, humidified air through a small tube placed in the nostrils - can improve exercise tolerance in adults with heart failure who are entering a cardiac rehabilitation program. The main questions it aims to answer are:

* Can HFNC help people with heart failure exercise for a longer time during a treadmill test?
* Does HFNC lower how hard people feel they are working during exercise?

Researchers will compare exercise performance with HFNC to exercise performance without HFNC to see if HFNC helps people with heart failure tolerate exercise better.

Participants will:

* Complete two treadmill exercise tests, one with HFNC and one without, in a randomly assigned order
* Wait 48 to 72 hours between the two tests to allow full recovery
* Have their heart rate, blood pressure, oxygen level, and breathing rate measured before and after each test

Conditions

  • Heart Failure
  • Exercise Tolerance (Measured in Minutes)
  • Cardiac Rehabilitation

Interventions

DEVICE

High-Flow Nasal Cannula (HFNC)

HFNC delivered via AIRVO 2™ (Fisher \& Paykel Healthcare, Auckland, New Zealand) with a nasal cannula at 50-60 L/min, FiO₂ 0.21, temperature 34-37°C. The cannula is removed immediately after the test is completed.

Sponsors & Collaborators

  • Universidad de Santiago de Chile

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2026-10-31
Completion
2027-03-31

Countries

  • Chile

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07613762 on ClinicalTrials.gov